| 2.47 0.005 (0.2%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 4.01  |
1-year : | 4.74 |
| Resists | First : | 3.43 |
Second : | 4.05 |
| Pivot price | 2.83 |
|||
| Supports | First : | 2.42 | Second : | 2.01 |
| MAs | MA(5) : | 2.5 |
MA(20) : | 3.01 |
| MA(100) : | 4.13 |
MA(250) : | 7.07 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.1 |
D(3) : | 3.8 |
| RSI | RSI(14): 25.6  |
|||
| 52-week | High : | 16.52 | Low : | 2.42 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ME ] has closed above bottom band by 25.3%. Bollinger Bands are 4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.52 - 2.53 | 2.53 - 2.55 |
| Low: | 2.41 - 2.42 | 2.42 - 2.44 |
| Close: | 2.45 - 2.47 | 2.47 - 2.49 |
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Fri, 31 Jan 2025
23andMe Holding Co. (ME) Launches New Genetic Report on Osteoporosis - StreetInsider.com
Tue, 28 Jan 2025
23andMe Holding Co. (ME) to explore strategic alternatives, including possible sale - StreetInsider.com
Tue, 28 Jan 2025
23andMe Puts Itself Up for Sale: Major DNA Testing Company Could Change Hands - StockTitan
Tue, 28 Jan 2025
23andMe Special Committee Announces Exploration of Strategic Alternatives - GlobeNewswire
Wed, 08 Jan 2025
23andMe Launches Discover23 to Help Accelerate Large-Scale - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 20 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 3.6 (%) |
| Held by Institutions | 33.3 (%) |
| Shares Short | 1,030 (K) |
| Shares Short P.Month | 1,150 (K) |
| EPS | -13.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.69 |
| Profit Margin | 0 % |
| Operating Margin | -178.1 % |
| Return on Assets (ttm) | -25.8 % |
| Return on Equity (ttm) | -154.3 % |
| Qtrly Rev. Growth | -33.6 % |
| Gross Profit (p.s.) | 4.54 |
| Sales Per Share | 10.14 |
| EBITDA (p.s.) | -11.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -138 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.19 |
| PEG Ratio | 0 |
| Price to Book value | 0.32 |
| Price to Sales | 0.24 |
| Price to Cash Flow | -0.36 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|